Semaglutide (5 mg Vial) Dosage Protocol

Educational guide for reconstitution and weekly dosing of Semaglutide, a GLP-1 receptor agonist studied for metabolic health and body composition.

Dosing & Reconstitution Guide

Educational guide for reconstitution and daily dosing

Subcutaneous Protocol (2 mL = 2.5 mg/mL)

Frequency: Inject once or twice daily subcutaneously. Due to the compound's plasma half-life of approximately 3.8–6.9 hours, twice-daily (BID) dosing may provide more sustained NNMT inhibition. Note: A single 5 mg vial provides approximately 2–3 weekly doses depending on maintenance dose.

Reconstitution Steps

1. Remove the vial from freezer storage (−20 °C / −4 °F) and allow to equilibrate at room temperature for 15–20 minutes.
2. Draw 2.0 mL bacteriostatic water with a sterile syringe.
3. Inject slowly down the vial wall; avoid foaming.
4. Gently swirl/roll until dissolved—solution should be clear (do not shake).
5. Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light; use within 2–4 weeks.

Biological Action

Semaglutide represents a synthetic GLP-1 receptor agonist that mimics the effects of glucagon-like peptide-1, a naturally occurring incretin hormone.

As a long-acting GLP-1 analog, Semaglutide binds to GLP-1 receptors to enhance insulin secretion, suppress glucagon release, and promote satiety through delayed gastric emptying.

Semaglutide has been extensively studied for its effects on glycemic control, weight management, and metabolic health in clinical settings.

Potential Benefits & Side Effects

Findings from endocrinology and metabolic research.

• May support metabolic health and body composition regulation
• Associated with improved glycemic control and appetite regulation
• Potential to support cardiovascular health markers
• May cause gastrointestinal side effects; gradual dose escalation recommended
• Well-studied compound with clinical data available; gradual titration advised

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.
5. Slow injection may minimize any stinging sensation associated with the compound.

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes for each administration; dispose in a sharps container.
• Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
• Inject slowly; a mild stinging sensation may occur due to the quinolinium structure.
• Document daily dose and site rotation to maintain consistency.
• The 10 mg vial format is suited for short-term tolerance assessment; extended protocols require multiple vials.

References